Nissenkorn I, Lavie G, Keisari Y, Leib Z, Vilcovsky E, Servadio C, Shachter H
Department of Urology, Beilinson Medical Center, Petah, Tikva, Israel.
Eur Urol. 1987;13(4):246-50. doi: 10.1159/000472788.
Twenty-four patients with transitional cell carcinoma of the bladder, who had failed thiotepa therapy, were subjected to immunotherapy with intravesical bacillus Calmette-Guérin (BCG) by a modification of the Morales protocol. The results show a marked decline in the number of recurrent tumors following BCG immunotherapy. From a cumulative recurrence of 1 in 8.3 months, recurrences declined to 1 in 82 months. In parallel with the clinical follow-up, the level of the in vivo activation of peripheral blood monocytes of the treated patients, as a result of immunostimulation with BCG, was monitored by the quantitation of oxidative burst products released by the cells. The oxidative burst capacity of peripheral blood monocytes were found to undergo an increase of 80-140% in 5 of 10 patients tested. The patients with a high level of activation of peripheral blood monocytes did not have tumor recurrence while 3 of the 5 patients who did not show an increase in the oxidative burst had recurrent tumors. The possibilities for utilizing the oxidative burst test as an early indicator for distinction between patients who will respond to BCG immunotherapy and nonresponders is discussed.
24例膀胱移行细胞癌患者，噻替派治疗失败后，采用改良的莫拉莱斯方案进行膀胱内卡介苗（BCG）免疫治疗。结果显示，BCG免疫治疗后复发肿瘤数量显著下降。复发从每8.3个月1次累积发生率，降至每82个月1次。在临床随访的同时，通过定量检测细胞释放的氧化爆发产物，监测经BCG免疫刺激后治疗患者外周血单核细胞的体内活化水平。在10例检测患者中的5例中，发现外周血单核细胞的氧化爆发能力增加了80%-140%。外周血单核细胞活化水平高的患者没有肿瘤复发，而氧化爆发未增加的5例患者中有3例出现肿瘤复发。本文讨论了利用氧化爆发试验作为早期指标，区分对BCG免疫治疗有反应和无反应患者的可能性。
